Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:52 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer
NCT05384119 · Tvardi Therapeutics, Incorporated · PHASE1 · terminated · last registry update 2026-09-24 · Breast cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study was terminated prior to Phase 2 due to slow accrual.” | – | Registry record, Tvardi Therapeutics, Incorporated |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CCND1 in breast cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-10-26Phase 3 first posted: Jiangsu HengRui Medicine Co., Ltd., HRS-6209 + Letrozole + Dalpciclib/Palbociclib + Letrozole/Anastrozole (NCT07894328)
- 2026-09-29Results posted on the registry: Arvinas Estrogen Receptor, Inc., Vepdegestrant + Vepdegestrant (NCT04072952)
- 2026-09-03Phase 3 first posted: SWOG Cancer Research Network, NSAI + CDK4/6i + NSAI + CDK4/6i + Capivasertib (NCT07802626)
- 2026-07-21Phase 3 first posted: UNICANCER, a drug against CCND1 (NCT07717450)
- 2026-07-06Phase 3 first posted: Daiichi Sankyo, Trastuzumab deruxtecan + Trastuzumab (NCT07683754)
- 2026-06-25Also stopped (terminated): SOLTI Breast Cancer Research Group, Ribociclib + Letrozole OR Fulvestrant + Palbociclib + Letrozole OR Fulvestrant (NCT05207709)
- 2026-03-25Phase 3 first posted: BeOne Medicines, BGB-43395 + Letrozole (NCT07492641)
- 2026-02-24Results posted on the registry: City of Hope Medical Center, Fulvestrant + Letrozole (NCT02778685)
- 2026-02-12Results posted on the registry: Alliance Foundation Trials, LLC., palbociclib + trastuzumab (NCT02947685)
- 2025-11-24Results posted on the registry: Sanofi, Amcenestrant + Palbociclib (NCT03284957)
- 2025-11-24Also stopped (terminated): Sanofi, Amcenestrant + Palbociclib (NCT03284957)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision